Tag: Saredutant

Recent research in *Nature* found that activating the neurokinin 2 receptor (NK2R) in animal models led to weight loss by increasing energy expenditure and suppressing appetite. This makes NK2R a promising new drug target for cardiometabolic diseases, shifting its historical focus from other therapeutic areas, such as irritable bowel syndrome and depression.

The neurokinin 2 (NK2) receptor, a member of the tachykinin receptor family, is predominantly found on smooth muscle in the periphery, including the gastrointestinal, respiratory, and urinary tracts. A range of compounds, known as neurokinin 2 receptor antagonists, have been developed to block the action of the endogenous ligand neurokinin A (NKA) at these receptors, though many have failed to reach the market despite initial promise.